secwatch.observer — SEC 8-K summary
======================================

Issuer:     Telomir Pharmaceuticals, Inc. (TELO)
CIK:        0001971532
Form:       8-K
Filed at:   2025-12-22T23:59:59+00:00
Accession:  0001493152-25-028620
Event type: leadership
Sentiment:  positive
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud

Telomir Pharmaceuticals Approves CEO Compensation Adjustments Including Incentive Payouts and Salary Increase
--------------------------------------------------------------------------------

- CEO Erez Aminov received a 2025 short-term incentive payout of $400,000 for operational and financing achievements.
- Contingent milestone payout of $150,000 approved for future FDA acceptance of the Telomir-1 IND submission.
- Transaction advisory award of 3% of the total TELI acquisition value granted for leadership in negotiating the potential acquisition.
- Base salary adjusted to $500,000 effective January 1, 2026, based on external benchmarking.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971532/000149315225028620/0001493152-25-028620-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971532/000149315225028620/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-028620

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer